Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 25 (September 1), 2005: pp. 5950-5959
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.04.127
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Madhusudan, S.
Right arrow Articles by Ganesan, T. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Madhusudan, S.
Right arrow Articles by Ganesan, T. S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer

Srinivasan Madhusudan, Sethupathi R. Muthuramalingam, Jeremy P. Braybrooke, Susan Wilner, Kulwinder Kaur, Cheng Han, Susan Hoare, Frances Balkwill, Trivadi S. Ganesan

From Cancer Research UK Medical Oncology Unit, University of Oxford, Churchill Hospital, Oxford; and Cancer Research UK Translational Oncology Laboratory, Barts and the London, Queen Mary's School of Medicine and Dentistry, Charterhouse Square, London, United Kingdom

Address reprint requests to Trivadi S. Ganesan, MD, PhD, FRCP, Cancer Research UK Cancer Centre, Churchill Hospital, OX3 7LJ Oxford, United Kingdom; e-mail: ganesan{at}cancer.org.uk


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
 REFERENCES
 
PURPOSE: Convincing data support the link between inflammation and ovarian cancer. Tumor necrosis factor-alpha (TNF-{alpha}), a major mediator of inflammation, is chronically produced in the ovarian tumor microenvironment and may enhance tumor growth and invasion by inducing the secretion of cytokines, proangiogenic factors, and metalloproteinases. Etanercept is a recombinant human soluble p75 TNF receptor that binds to TNF-{alpha} and renders it biologically unavailable. In the current study, we sought to determine the toxicity, biologic activity, and therapeutic efficacy of etanercept in recurrent ovarian cancer.

PATIENTS AND METHODS: We initiated a phase I-B, nonrandomized, open-label study in patients with recurrent ovarian cancer. Etanercept was administered subcutaneously at a dose of 25 mg twice weekly (cohort one) and 25 mg thrice weekly (cohort two) until disease progression.

RESULTS: Thirty patients were recruited (cohort one, 17 patients; cohort two, 13 patients). Eighteen of the 30 patients (cohort one, 11 patients; cohort two, seven patients) completed ≥ 12 weeks of treatment. Six patients achieved prolonged disease stabilization (cohort one, two patients [40 and 25 weeks]; cohort two, four patients [34, 24, 22, and 24 weeks]). A significant rise in immunoreactive TNF was seen in all patients (pretreatment compared with end of treatment). A phytohemagglutinin-stimulated whole-blood cytokine assay showed a significant fall in interleukin-6 (cohort one [11 of 17]) and CCL2 (cohort one [13 of 17]) levels. Common adverse effects were injection-site reactions and fatigue.

CONCLUSION: We provide evidence for the biologic activity and safety of etanercept in recurrent ovarian cancer. Our data suggest possible clinical activity that must be confirmed in future studies.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
 REFERENCES
 
Advanced ovarian cancer is the most common cause of death resulting from gynecological cancer and is the fourth leading cause of cancer mortality in women. Despite advances in therapy, the overall survival of patients with recurrent ovarian cancer remains poor. Several chemotherapeutic agents have shown significant antitumor activity in recurrent disease,1 but treatment-related toxicity causes considerable morbidity. Hence, the development of novel therapies to improve patient outcomes remains a high priority.

Convincing data support the link between inflammation and ovarian cancer.2-5 Tumor necrosis factor-alpha (TNF-{alpha}) is a major mediator of inflammation.6,7 TNF-{alpha} is a 17-kd polypeptide that binds as a homotrimer to p55 and p75 TNF-{alpha} receptors (TNFRs I and II, respectively). These receptors exist both on the cell surface and in soluble form. The soluble receptors are involved in the regulation of bioavailability of TNF-{alpha}.8,9 TNF-{alpha} has a bimodal role in cancer.10 Local administration of high-dose TNF-{alpha} is antiangiogenic and has a powerful antitumor effect.11 On the other hand, endogenous TNF-{alpha} chronically produced in tumor microenvironment enhances tumor growth and invasion by inducing other cytokines/chemokines involved in cancer progression (such as interleukin-6 [IL-6] and CCL2), proangiogenic factors (such as vascular endothelial growth factors, basic fibroblast growth factor, CXCL8, and thymidine phosphorylase), and matrix metalloproteinases (MMPs).10,12-16 Direct evidence for the role of TNF-{alpha} in malignancy comes from mice in which TNF-{alpha} has been deleted. TNF-{alpha} and TNFR knockout mice are resistant to skin carcinogenesis.17-20

Several preclinical studies confirm the importance of TNF-{alpha} in ovarian cancer pathogenesis. TNF-{alpha} functions as an autocrine and a paracrine growth factor in ovarian cancer.21 TNF-{alpha} converts ascitic tumor xenografts to solid peritoneal tumors,22 and tumor cells secreting TNF-{alpha} show enhanced metastasis in nude mice.23 TNF-{alpha} induces MMP-9, IL-6, and CCL2 production in tumor microenvironment that are important for ovarian cancer progression.24-26 Stimulation of ovarian cancer cell proliferation by IL-1ß can be blocked partially by an antibody against TNF-{alpha}, by soluble (s)TNF-{alpha} receptor (which reduces the bioavailability of TNF-{alpha}), and by TNF-{alpha} antisense mRNA.21,27

In human studies, TNF-{alpha} mRNA and protein expression is seen predominantly within ovarian tumor epithelial islands.28 TNFRI (p55 receptor) is localized to tumor and stromal cells, and TNFRII (p75 receptor) is localized to the leukocyte infiltrate.28 A positive correlation is seen between tumor grade and the extent of TNF-{alpha} expression in ovarian cancer.28 Immunohistochemical analysis of tissue specimens suggests that TNF-{alpha} positivity is confined to malignant tissue and the normal ovarian tissue is negative for TNF-{alpha} staining.29 Patients with epithelial ovarian cancer have elevated serum levels of TNF-{alpha} and p55 and p75 receptors.30,31 TNF-{alpha} is implicated in the induction of CCL2, a predominant chemokine in the ovarian tumor microenvironment that regulates CD8/CD68 infiltrate.32,33 It also causes defective expression of the chemokine receptor CCR2 in the ovarian cancer microenvironment.34 TNF-{alpha} stimulates IL-6 production, a potent growth factor that directly stimulates angiogenesis.35 Patients with ovarian cancer have elevated levels of IL-6 in serum and ascitic fluid.31,36 Hence, TNF-{alpha} blockade is a novel approach to ovarian cancer therapy.

TNF-{alpha} plays a central role in the pathogenesis of rheumatoid arthritis (RA), which lead to the development of anti-TNF-{alpha} therapy for RA. Etanercept (Enbrel; Immunex Corp, Seattle, WA) is a recombinant dimer of human soluble p75 TNF-{alpha} receptor (sTNF-{alpha} receptor).37,38 It acts as a competitive inhibitor of TNF-{alpha}, binding to cell surface TNF-{alpha} receptor, and hence inhibits biologic activity of TNF-{alpha}. Etanercept binds reversibly to TNF-{alpha}. Etanercept has an approximately 50-fold greater affinity for TNF-{alpha} in a binding-inhibition assay and is at least 1,000 times more efficient than the monomeric sTNF-{alpha} receptor. The half-life of etanercept is five times that of monomeric sTNF-{alpha} receptor. These characteristics of etanercept result in its greater ability to neutralize the biologic effects of TNF-{alpha}. The pharmacokinetics of etanercept has been studied in 11 human trials involving 285 subjects. It is absorbed slowly from a subcutaneous (SC) injection site and achieves a maximum serum concentration approximately 48 hours after a single dose. The elimination half-life is 70 hours with a bioavailability of 76%.39

Based on the above biochemical, preclinical, and clinical data, we initiated a study to evaluate the role of etanercept in patients with recurrent ovarian cancer. The primary objectives of the study were to evaluate toxicity, biologic activity, and clinical activity of etanercept in patients with recurrent ovarian cancer.


   PATIENTS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
RESULTS
 DISCUSSION
 Authors' Disclosures of...
 REFERENCES
 
Patient Selection
This study was conducted in compliance with the declaration at Helsinki, Tokyo, Venice, and Hong Kong (1989). Local research ethics committee approval was obtained. All patients provided written informed consent. Patients were eligible to participate in the study if they had advanced, histologically confirmed ovarian cancer with measurable or evaluable lesions and documented progression within 2 months before entry into the study. Patients ≥ 18 years of age, nonpregnant, nonlactating, using effective contraception if liable to become pregnant, with a performance status (World Health Organization) of 0, 1, or 2, and expected survival longer than 3 months were considered for the study. An absolute granulocyte count of more than 1.5 x 109/L, platelet count ≥ 100 x 109/L, adequate renal function (serum creatinine ≤ 0.15 mmol/L or EDTA clearance > 40 mL/min), adequate hepatic function (bilirubin, alkaline phosphatase, or transaminases ≤ 2x the upper limit of normal; if there were liver metastases, then ALP or transaminases ≤ 5x the upper limit of normal), and a normal coagulation profile were essential. Patients were also required to self-inject etanercept or have a designee who could do so.

Treatment Plan
The dose of etanercept in cohort one was 25 mg twice weekly given SC (similar to the dose used in patients with RA). In view of the biologic and clinical effect in cohort one, we extended the study to recruit patients who would receive etanercept 25 mg thrice weekly (cohort two). This was to investigate if it would achieve a better therapeutic response and biologic effect. All patients were expected to receive at least 12 weeks of treatment, and responding patients continued therapy until disease progression.

Evaluation Protocol at Baseline and During Therapy
History, physical examination, and performance status assessments were performed at baseline and days 1, 8, and 28, and every 4 weeks thereafter. Quality-of-life (QOL) assessments using the European Organization for Research and Treatment of Cancer QLQ-C30 (version 3) proforma were performed on day 1 and every 4 weeks from then on. Biochemical evaluation (serum sodium, potassium, glucose, urea, creatinine, alkaline phosphatase, total bilirubin, AST, and gamma glutamyl transferase) and hematologic evaluation (hemoglobin, white cell count, and platelet count) were performed at baseline, days 1, 8, and 28, and every 4 weeks thereafter. For the assessment of biologic responses, blood samples were collected at baseline, 24 hours postetanercept (day 1), days 7 and 28, and every 4 weeks thereafter (in cohort two, additional samples were collected on days 14, 21, and 77). Radiologic evaluation (computed tomography, x-ray) was performed at baseline and at 12 weekly intervals until disease progression. Complete response was defined as disappearance of all clinical evidence of active tumor for a minimum of 4 weeks and normalization of tumor marker (CA-125) and tumor-related biochemical abnormalities. Partial response was defined as ≥ 50% decrease in the sum of the diameters of measured lesions. Stable disease (SD) was defined as less than 25% decrease or less than 25% increase in the sum of the longest perpendicular lesion diameter. An increase of more than 25% in the size of any measured lesion or appearance of new lesions was defined as progressive disease. Patients who achieved either SD or tumor regression at 12 weeks were planned to receive additional courses of etanercept with disease-response evaluation performed at 12 weekly intervals. Therapy was terminated at disease progression, with the occurrence of a serious adverse event (including serious infection requiring hospital admission and antibiotics and serious allergic reactions to etanercept), or at the patient's request.

Toxicity evaluation was performed by using the National Cancer Institute's Common Toxicity Criteria.

Laboratory Procedures
TNF-{alpha} mediates the production of IL-6 and CCL2 in whole blood when stimulated by phytohemagglutinin (PHA) in vitro. The ability of etanercept to alter this response was assessed in sequential samples by using the whole-blood cytokine-release assay as reported previously.40 Briefly, whole blood from patients was stimulated with PHA, and release of IL-6 and CCL2 was measured after 24 hours of incubation at 37°C in 5% CO2. Fifteen-milliliter sterile, pyrogen-free Falcon tubes were spiked with sterilized, pyrogen-free Heparin (30 units/mL whole blood from CP Pharmaceuticals Ltd, Wrexham, United Kingdom). One tube of each pair was spiked further with PHA (2 µg/mL whole blood from Bio-Stat Diagnostic Systems, Stockport, United Kingdom). Twenty milliliters of blood was collected from the patient and split equally into a pair of prepared Falcon tubes labeled either "heparin + PHA" or "heparin" (control). Blood was incubated at 37°C for 24 hours, then the tubes were centrifuged at 200 g for 10 minutes at 4°C, and plasma was aspirated, frozen, and stored at –80°C until assayed. Ten milliliters of blood was also collected and processed immediately for measuring TNF-{alpha} levels in unstimulated samples. Similarly, CCL2, MMP-3, sTNFRI, and sE-selectin levels in the plasma were measured in unstimulated samples, because significant reductions have been reported in patients with RA who were receiving anti-TNF therapy.41

All experiments were performed in duplicate, following the protocols provided by the manufacturer (human TNF{alpha} ELISA kit [DTA50; R & D Systems, Minneapolis, MN], human IL-6 ELISA kit [D6050; R & D Systems], human CCL2 ELISA kit [DCP00; R & D Systems], human MMP-3 ELISA kit [RPN 2613; Amersham, Biosciences Ltd, Chalfont St Giles, United Kingdom], human sTNFRI ELISA kit [DRT100; R & D Systems], and human sE-selectin ELISA kit [BBE 2B; R & D Systems]). All results are expressed in pg/mL (except for MMP-3 and sE-selectin, which are expressed in ng/mL).

Statistical Analysis
This was a phase I-B study with a primary end point of toxicity, biologic activity, and efficacy. It was also planned that the study would be discontinued if no responses were observed in the first 14 patients in each cohort. The Wilcoxon matched-pairs signed-ranks test was performed to analyze the serial changes in blood TNF-{alpha}, IL-6, CCL2, MMP-3, sTNFRI, and sE-selectin levels. Regression analysis was performed to compare biologic responses between cohorts one and two.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
DISCUSSION
 Authors' Disclosures of...
 REFERENCES
 
Patients
Baseline characteristics of patients are summarized in Table 1. A total of 30 patients were recruited (cohort one, 17 patients; cohort two, 13 patients). Median age at diagnosis in cohort one was 55 years (range, 35 to 76) and in cohort two was 58 years (range, 39 to 66). Patients had been pretreated with surgery and multiple lines of chemotherapy before starting etanercept. Of the 30 patients, 10 received one line, 10 received two lines, and 10 received more than two lines of systemic therapy before etanercept. Four of 10 patients who had only one line of therapy were platinum resistant. Eleven of 17 patients in cohort one and seven of 13 patients in cohort two received ≥ 12 weeks of etanercept therapy.


View this table:
[in this window]
[in a new window]
  		Table 1. Patients

 
Toxicity
All 30 patients were assessable for toxicity. Treatment was well tolerated in all patients. There were no treatment-related deaths. The most common adverse effects reported during etanercept therapy were injection-site reactions (including skin rash, itching, pain, and swelling), fatigue, and anemia. The incidence and severity of skin rash, itching, and fatigue were higher in cohort two compared with cohort one (Table 2). One patient in cohort two developed Sjögren's syndrome after 8 months of etanercept therapy. She presented with polyarthropathy, polyneuropathy, erythema nodosum-like rash, dry eyes, and dry mouth. It was unclear whether this was related to etanercept. However, therapy was discontinued. She was started on prednisolone and hydroxychloroquine, with significant symptomatic improvement.


View this table:
[in this window]
[in a new window]
  		Table 2. Toxicity

 
No significant biochemical abnormalities resulting from etanercept were reported in any patients.

Disease Response
Eighteen patients (cohort one, 11 patients; cohort two, seven patients) who had at least 12 weeks of therapy were available for disease-response evaluation. No complete or partial responses were seen. Six patients achieved prolonged SD while on etanercept therapy (two patients in cohort one and four patients in cohort two; Table 3). Patient OV2 and OV11 in cohort one achieved SD for 25 and 40 weeks, respectively, and patients OV19, OV25, OV26, and OV28 in cohort two achieved SD for 22, 34, 24, and 24 weeks, respectively. In patient OV25, etanercept was stopped because she developed Sjögren's syndrome during therapy. Seventeen of 30 patients were alive after entry into this study and five of 17 who had SD were free of progression at 24 weeks.


View this table:
[in this window]
[in a new window]
  		Table 3. Characteristics of Patients Who Had Stable Disease

 
CA-125 Levels in Patients Who Achieved SD
All patients had a documented rise in CA-125 levels before initiation of etanercept therapy (Fig 1). Patient OV2 had a more than 50% reduction in CA-125 levels during etanercept therapy. Patients OV19 and OV25 had a less than 50% reduction in CA-125 levels while on therapy. No significant change in CA-125 level was seen in patients OV11 and OV28 until disease progression. Patient OV26 had doubling of CA-125 level at the time of disease progression. No CA-125 responses were seen in nonresponders.



View larger version (16K):
[in this window]
[in a new window]
  		Fig 1. CA-125 levels. Serial CA-125 levels in patients who had stable disease is shown here. In patient OV2, a significant fall in CA-125 was demonstrated with therapy.

 
QOL Assessments
Serial QOL assessments using the European Organization for Research and Treatment of Cancer QLQ-C30 (version 3) was available for 29 of 30 patients (Fig 2). Improvements in mean function scales, mean symptom scales, and global functions were seen in patients who had SD. All others reported overall deterioration in QOL, largely because of symptomatic deterioration resulting from disease progression.



View larger version (18K):
[in this window]
[in a new window]
  		Fig 2. Quality of life: comparison of quality-of-life assessments between patients who had stable disease (SD) and nonresponders, showing an overall improvement in patients who had SD compared to nonresponders. The dashed line represents nonresponders, and the black line represents patients who had SD. (A) Mean function scale; (B) mean symptom scale; (C) global function scale.

 
Biologic Response
Plasma TNF-{alpha} levels with therapy. Serial blood samples were available for biologic response analysis in patients (Fig 3). In unstimulated blood samples, TNF-{alpha} was measured as described previously. Serial changes in plasma TNF-{alpha} levels in cohorts one and two are summarized in Table 4. Minimal immunoreactive TNF-{alpha} was detected in pretreatment samples. However, within 24 hours of etanercept administration, a significant rise in immunoreactive TNF-{alpha} was seen in all patients. In addition, the samples were checked for biologic activity in a TNF-{alpha} bioassay, which was negative. A statistically significant increase in TNF-{alpha} was demonstrated (pretreatment compared with end-of-treatment values) in both cohorts one (P = .008) and two (P = .02). Regression analysis did not reveal any significant differences between cohorts (P = .63).



View larger version (26K):
[in this window]
[in a new window]
  		Fig 3. Tumor necrosis factor-alpha (TNF-{alpha}) levels. Serial changes in mean plasma TNF-{alpha} levels in patients. A statistically significant increase was seen in both cohorts. Error bars indicate the standard deviation. The Wilcoxon matched-pairs signed-ranks test was performed to analyze the serial changes. (A) Cohort one; (B) cohort two.

 

View this table:
[in this window]
[in a new window]
  		Table 4. Plasma Tumor Necrosis Factor-Alpha Levels in Patients

 
Whole-blood cytokine-release assay (IL-6). A whole-blood cytokine-release assay was performed to assess the effect of etanercept on the release of IL-6 in the whole blood when stimulated by PHA (Fig 4). At each time point, IL-6 levels were measured in either the presence or absence of PHA as described previously. Mean levels in PHA-stimulated samples over the whole time course are summarized in Table 5. In cohort one, a consistent fall in PHA-stimulated IL-6 was seen in 11 of 17 patients; in cohort two, 8 of 13 patients showed a fall in PHA-stimulated IL-6 levels (pretreatment values compared to end-of-treatment values). A statistically significant decrease in PHA-stimulated IL-6 was demonstrated (pretreatment compared with end-of-treatment values) in cohort one (P = .03) but not in cohort two (P = .60). Regression analysis did not reveal any significant differences between the two cohorts (P = .78).



View larger version (22K):
[in this window]
[in a new window]
  		Fig 4. Interleukin-6 (IL-6) levels. A whole-blood cytokine assay (IL-6) was performed in serial samples in both cohorts. A statistically significant decrease was seen in cohort one. Error bars indicate the standard deviation. The Wilcoxon matched-pairs signed-ranks test was performed to analyze the serial changes. (A) Cohort one; (B) cohort two.

 

View this table:
[in this window]
[in a new window]
  		Table 5. Whole-Blood Cytokine-Release Assay

 
Whole-blood cytokine-release assay (CCL2). A whole-blood cytokine-release assay was performed to assess the effect of etanercept on the release of CCL2 in the whole blood when stimulated by PHA (Fig 5). At each time point, CCL2 levels were measured in either the presence or absence of PHA as described previously. Mean levels in PHA-stimulated samples over the whole time course are summarized in Table 5. A consistent fall in PHA-stimulated CCL2 levels was seen in the patients (cohort one, 13 of 17; cohort two, 7 of 13). A statistically significant decrease in PHA-stimulated CCL2 was demonstrated (pretreatment compared with end-of-treatment values) in cohort one (P = .006) but not in cohort two (P = .40). Regression analysis did not reveal any significant differences between cohorts (P = .22).



View larger version (26K):
[in this window]
[in a new window]
  		Fig 5. CCL2 levels. A whole-blood cytokine assay (CCL2) was performed in serial samples in both cohorts. A statistically significant decrease was seen in cohort one. Error bars indicate the standard deviation. The Wilcoxon matched-pairs signed-ranks test was performed to analyze the serial changes. (A) Cohort one; (B) cohort two.

 
Plasma levels of CCL2, MMP-3, sTNFRI, and sE-selectin in unstimulated samples. Serial blood samples from the first 13 patients in cohort one were available for analysis. Mean plasma levels of CCL2, MMP-3, sTNFRI, and sE-selectin are summarized in Table 6. A significant decrease in sE-selectin was demonstrated (pretreatment compared with day 7, P = .02). For sTNFRI, a significant reduction was also demonstrated (pretreatment compared with day 1, P = .02).


View this table:
[in this window]
[in a new window]
  		Table 6. Mean Plasma Levels of CCL2, MMP-3, soluble TNFR1, and Soluble E-Selectin (unstimulated samples)

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
Authors' Disclosures of...
 REFERENCES
 
This is the first trial of a TNF-{alpha} inhibitor in ovarian cancer. Etanercept was found to be safe and well tolerated in this study. Adverse effects reported were similar to those seen in patients with RA. Most adverse effects required no medical intervention, although etanercept was stopped in one patient because of the development of Sjögren's syndrome.

Because etanercept is likely to be cytostatic rather than cytotoxic, we expected to see SD rather than partial or complete responses. In fact, this was demonstrated in six patients. Patients were evaluable for disease response if they had at least 12 weeks of therapy (a total of 18 patients). Overall, 33% of patients achieved SD (57% [4 of 7] of patients in cohort two achieved SD, and 18% [2 of 11] of patients in cohort one achieved SD). Interesting observations were made in patients who achieved SD. First, these patients had stabilization or reduction in CA-125 levels with therapy. Second, they also had overall improvements in QOL compared to nonresponders, suggesting clinical benefit with therapy. Adverse effects caused by etanercept had little impact on QOL, which is in contrast to conventional chemotherapy used in recurrent ovarian cancer that causes significant morbidity in patients. In patients, withdrawal of cytotoxic treatment can lead to a period of stabilization of disease; however, this is unlikely to explain our result, because all patients had documented disease progression (as assessed by computed tomography and rising CA-125 levels) and had a minimum 1-month washout period before starting etanercept.

A substantial effect of etanercept on the TNF-{alpha} pathway was demonstrated for the first time in patients with ovarian cancer in our study. A significant increase in immunoreactive TNF-{alpha} was seen in patients within 24 hours of initiation of etanercept therapy. This rapid elevation of TNF-{alpha} is due to binding to etanercept and continued at all subsequent time points (days 7, 28, 56, and 84). TNF-{alpha} levels reached statistical significance in both cohorts one and two, confirming the biologic effect of etanercept. In addition, the elevated TNF-{alpha} levels in peripheral blood were not biologically active in a bioassay. Therefore, it is unlikely that the levels of biologically active TNF-{alpha} are elevated in the tumor microenvironment with etanercept treatment, given our results from the peripheral blood assays and those reported in patients with RA. Studies in rheumatoid joints showed reduction in cytokines such as TNF-{alpha} with etanercept (reviewed in refs 38 and 39). However, biologic marker analysis in serial tumor samples (or ascitic fluid samples) in future studies may be able to address this issue directly.

We also evaluated whether the depletion of biologically active TNF-{alpha} could have a functional effect on target cells. There was a significant decline in the ability of PHA to stimulate IL-6 and CCL2 in peripheral blood that correlated with duration of treatment, which reached statistical significance in cohort one but not in cohort two. This could be because of variability between patients in the amount of chemotherapy that patients received before etanercept, which could affect lymphocyte function. In patients who had SD, there was a consistent time-dependent decrease in IL-6 and CCL2, suggesting a correlation with response (Fig 6). The effect of etanercept is also suggested by stable CA-125 levels over time in these patients when they were doubling before treatment. Moreover, this reduction is consistent with those seen in patients with RA who show reduction in serum levels of IL-6, chemokines, and acute phase proteins.37 Given the substantial biologic evidence for the success of anti-TNF therapy in RA joints (including diminished cytokine/chemokine [TNF, IL-6, CCL2] production, reduced levels of vascular endothelial growth factor and angiogenesis, and restoration of depressed T-cell immune responses), a similar cytokine response within the tumor microenvironment is likely to have contributed to the prolonged SD seen in six patients in our study. Similarly, in unstimulated plasma samples, there was a significant decrease in plasma sE-selectin and sTNFRI levels.



View larger version (29K):
[in this window]
[in a new window]
  		Fig 6. Cytokine response in patients who had stable disease in cohort one. (A) There was a consistent increase in plasma tumor necrosis factor-alpha (TNF-{alpha}) levels with therapy (compared to pretreatment values) in patients OV2 and OV11. (B and C) Trends in interleukin-6 (IL-6) and CCL2 levels in peripheral blood stimulated by phytohemagglutinin are shown. There was a reduction in the levels of IL-6 and CCL2 in both patients.

 
We recently reported a phase II study of etanercept in patients with metastatic breast cancer.42 Sixteen patients received etanercept 25 mg SC twice weekly. The most common adverse effects were injection-site reactions, fatigue, loss of appetite, nausea, headache, and dizziness. A brief period of SD was seen in one patient, which lasted for 16.4 weeks. Immunoreactive TNF-{alpha} was elevated within 24 hours of therapy and persisted until the end of treatment (days 7, 28, 56, and 84). PHA-stimulated cytokine-release assay showed a consistent decrease in IL-6 and CCL2 levels compared with pretreatment values in serial blood samples (days 1, 7, 28, 56, and 84).42 The role of etanercept has also been investigated in hematologic disorders. Although etanercept has shown some clinical activity in myelodysplasia, myelofibrosis, and chronic lymphocytic leukemia,43,44 it did not produce any disease responses in myeloma.45

A key issue for future analysis is whether higher or more frequent doses of etanercept could produce more tissue depletion in cancer patients and whether blockade with other anti-TNF approaches (some with longer half-lives) could enhance biologic effectiveness. D2E7 is a fully human anti-TNF monoclonal antibody and an irreversible inhibitor of TNF-{alpha}.46 Trial of D2E7 in ovarian cancer is likely to produce interesting results. Other agents in various stages of development include infliximab (a chimeric immunoglobulin G1 monoclonal antibody targeted against TNF), pegylated recombinant human sTNFR type 1, pegylated humanized anti-TNF fragment (CDP870), and TNF synthesis inhibitors (p38 kinase inhibitors).46 Other potential roles of etanercept include its use in antiangiogenic combinations to block multiple pathways. Etanercept in combination with low-dose methotrexate chemotherapy has been evaluated in patients with RA.47 Combination therapy was found to be safe and efficacious. Whether a combination of etanercept with "metronomic" scheduling of chemotherapy (eg, low-dose cyclophosphamide and methotrexate)48 is likely to produce an enhanced antiangiogenic effect in patients with cancer remains to be established.

We provide evidence for the biologic activity and safety of etanercept in recurrent ovarian cancer. Our data suggest possible clinical activity that must be confirmed in future studies.


   Authors' Disclosures of Potential Conflicts of Interest
TOP
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
REFERENCES
 
The authors indicated no potential conflicts of interest.


   Acknowledgment
 
We acknowledge the support of Wyeth for the provision of etanercept. We are grateful to patients for consenting to participate in the study.


   NOTES
 
Supported by Cancer Research UK.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
 REFERENCES
 
1. Harries M, Gore M: Part II: Chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol 3:537-545, 2002[CrossRef][Medline]

2. Coussens LM, Werb Z: Inflammation and cancer. Nature 420:860-867, 2002[CrossRef][Medline]

3. Balkwill F, Mantovani A: Inflammation and cancer: Back to Virchow? Lancet 357:539-545, 2001[CrossRef][Medline]

4. Ness RB, Cottreau C: Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459-1467, 1999[Abstract/Free Full Text]

5. Ness RB, Grisso JA, Cottreau C, et al: Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11:111-117, 2000[CrossRef][Medline]

6. Beutler BA: The role of tumor necrosis factor in health and disease. J Rheumatol 26:16-21, 1999 (suppl 57)

7. Hussain SP, Hofseth LJ, Harris CC: Radical causes of cancer. Nat Rev Cancer 3:276-285, 2003[CrossRef][Medline]

8. Choy EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907-916, 2001[Free Full Text]

9. Zambello R, Trentin L, Facco M, et al: Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes. Blood 96:647-654, 2000[Abstract/Free Full Text]

10. Balkwill F: Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13:135-141, 2002[CrossRef][Medline]

11. Lejeune FJ, Ruegg C, Lienard D: Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 10:573-580, 1998[CrossRef][Medline]

12. Ryuto M, Ono M, Izumi H, et al: Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 271:28220-28228, 1996[Abstract/Free Full Text]

13. Samaniego F, Markham PD, Gendelman R, et al: Inflammatory cytokines induce endothelial cells to produce and release basic fibroblast growth factor and to promote Kaposi's sarcoma-like lesions in nude mice. J Immunol 158:1887-1894, 1997[Abstract]

14. Yoshida S, Ono M, Shono T, et al: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17:4015-4023, 1997[Abstract]

15. Leek RD, Landers R, Fox SB, et al: Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 77:2246-2251, 1998[Medline]

16. Relf M, LeJeune S, Scott PA, et al: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969, 1997[Abstract/Free Full Text]

17. Moore RJ, Owens DM, Stamp G, et al: Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5:828-831, 1999 [Erratum: Nat Med 5:1087, 1999]

18. Suganuma M, Okabe S, Marino MW, et al: Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 59:4516-4518, 1999[Abstract/Free Full Text]

19. Lind MH, Rozell B, Wallin RP, et al: Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-kappaB inhibition. Proc Natl Acad Sci USA 101:4972-4977, 2004[Abstract/Free Full Text]

20. Arnott CH, Scott KA, Moore RJ, et al: Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 23:1902-1910, 2004[CrossRef][Medline]

21. Wu S, Boyer CM, Whitaker RS, et al: Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: Monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 53:1939-1944, 1993[Abstract/Free Full Text]

22. Malik ST, Griffin DB, Fiers W, et al: Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer 44:918-925, 1989[Medline]

23. Malik ST, Naylor MS, East N, et al: Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 26:1031-1034, 1990

24. Leber TM, Balkwill FR: Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br J Cancer 78:724-732, 1998[Medline]

25. Asschert JG, Vellenga E, Ruiters MH, et al: Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int J Cancer 82:244-249, 1999[CrossRef][Medline]

26. Negus RP, Turner L, Burke F, et al: Hypoxia down-regulates MCP-1 expression: Implications for macrophage distribution in tumors. J Leukoc Biol 63:758-765, 1998[Abstract]

27. Wu S, Meeker WA, Wiener JR, et al: Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-alpha) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-alpha. Gynecol Oncol 53:59-63, 1994[CrossRef][Medline]

28. Naylor MS, Stamp GW, Foulkes WD, et al: Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 91:2194-2206, 1993

29. Hassan MI, Kassim SK, Saeda L, et al: Ovarian cancer-induced immunosuppression: Relationship to tumor necrosis factor-alpha (TNF-alpha) release from ovarian tissue. Anticancer Res 19:5657-5662, 1999[Medline]

30. Gadducci A, Ferdeghini M, Castellani C, et al: Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer. Gynecol Oncol 58:184-188, 1995[Medline]

31. Moradi MM, Carson LF, Weinberg B, et al: Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 72:2433-2440, 1993[CrossRef][Medline]

32. Negus RP, Stamp GW, Relf MG, et al: The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 95:2391-2396, 1995

33. Negus RP, Stamp GW, Hadley J, et al: Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 150:1723-1734, 1997[Abstract]

34. Sica A, Saccani A, Bottazzi B, et al: Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J Immunol 164:733-738, 2000[Abstract/Free Full Text]

35. Kishimoto T, Akira S, Narazaki M, et al: Interleukin-6 family of cytokines and gp130. Blood 86:1243-1254, 1995[Free Full Text]

36. Kryczek I, Grybos M, Karabon L, et al: IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity. Br J Cancer 82:621-628, 2000[CrossRef][Medline]

37. Feldmann M: Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2:364-371, 2002[CrossRef][Medline]

38. Maini RN, Taylor PC: Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 51:207-229, 2000[CrossRef][Medline]

39. Alldred A: Etanercept in rheumatoid arthritis. Expert Opin Pharmacother 2:1137-1148, 2001[CrossRef][Medline]

40. Thavasu P, Propper D, McDonald A, et al: The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients. Cancer Res 59:3980-3984, 1999[Abstract/Free Full Text]

41. Charles P, Elliott MJ, Davis D, et al: Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163:1521-1528, 1999[Abstract/Free Full Text]

42. Madhusudan S, Foster M, Muthuramalingam SR, et al: A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 10:6528-6534, 2004[Abstract/Free Full Text]

43. Tsimberidou AM, Thomas D, O'Brien S, et al: Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol 50:237-242, 2002[CrossRef][Medline]

44. Steensma DP, Mesa RA, Li CY, et al: Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: Results of a pilot study. Blood 99:2252-2254, 2002[Abstract/Free Full Text]

45. Tsimberidou AM, Waddelow T, Kantarjian HM, et al: Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR: Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNF alpha levels during treatment. Leuk Res 27:375-380, 2003[CrossRef][Medline]

46. Palladino MA, Bahjat FR, Theodorakis EA, et al: Anti-TNF-alpha therapies: The next generation. Nat Rev Drug Discov 2:736-746, 2003[CrossRef][Medline]

47. Weinblatt ME, Kremer JM, Bankhurst AD, et al: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253-259, 1999[Abstract/Free Full Text]

48. Gasparini G: Metronomic scheduling: The future of chemotherapy? Lancet Oncol 2:733-740, 2001[CrossRef][Medline]

Submitted November 8, 2004; accepted May 9, 2005.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
E. R. Brown, K. A. Charles, S. A. Hoare, R. L. Rye, D. I. Jodrell, R. E. Aird, R. Vora, U. Prabhakar, M. Nakada, R. E. Corringham, et al.
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-{alpha} inhibitor, in patients with advanced cancer
Ann. Onc., July 1, 2008; 19(7): 1340 - 1346.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. H. Miller, S. Ancoli-Israel, J. E. Bower, L. Capuron, and M. R. Irwin
Neuroendocrine-Immune Mechanisms of Behavioral Comorbidities in Patients With Cancer
J. Clin. Oncol., February 20, 2008; 26(6): 971 - 982.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. E. Bower
Behavioral Symptoms in Patients With Breast Cancer and Survivors
J. Clin. Oncol., February 10, 2008; 26(5): 768 - 777.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. T. Stathopoulos, A. Kollintza, C. Moschos, I. Psallidas, T. P. Sherrill, E. N. Pitsinos, S. Vassiliou, M. Karatza, S. A. Papiris, D. Graf, et al.
Tumor Necrosis Factor-{alpha} Promotes Malignant Pleural Effusion
Cancer Res., October 15, 2007; 67(20): 9825 - 9834.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. M. McGowan, B. M. Ryan, A. D.K. Hill, E. McDermott, N. O'Higgins, and M. J. Duffy
ADAM-17 Expression in Breast Cancer Correlates with Variables of Tumor Progression
Clin. Cancer Res., April 15, 2007; 13(8): 2335 - 2343.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
N. Muthukumaran, K. E. Miletti-Gonzalez, A. K. Ravindranath, and L. Rodriguez-Rodriguez
Tumor Necrosis Factor-{alpha} Differentially Modulates CD44 Expression in Ovarian Cancer Cells
Mol. Cancer Res., August 1, 2006; 4(8): 511 - 520.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. W. Szlosarek, M. J. Grimshaw, H. Kulbe, J. L. Wilson, G. D. Wilbanks, F. Burke, and F. R. Balkwill
Expression and regulation of tumor necrosis factor {alpha} in normal and malignant ovarian epithelium.
Mol. Cancer Ther., February 1, 2006; 5(2): 382 - 390.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Madhusudan, S.
Right arrow Articles by Ganesan, T. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Madhusudan, S.
Right arrow Articles by Ganesan, T. S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online